Evaluation of Syndromic Algorithms for Managing Sexually Transmitted Infections Among Pregnant Women in Kenya

Pintye J^{1,2}, Drake AL¹, Unger JA³, Matemo D⁴, Kinuthia J⁴, McClelland RS^{1,5,6,7}, John-Stewart G^{1,5,6,8} for the Mama Salama Study Team

Departments of ¹Global Health, ²Nursing, ³Obstetrics and Gynecology, ⁵Medicine, ⁶Epidemiology, and ⁸Pediatrics, University of Washington, Seattle, USA ⁴Department of Research Programs, Kenyatta National Hospital, Nairobi, Kenya ⁷Institute of Tropical and Infectious Diseases, University of Nairobi, Kenya









Disclosures

No conflicts of interest to declare






Sexually Transmitted Infections (STIs)


Type of Agent	Pathogen/organism	Condition
Viruses	Human Papillomavirus	Warts
	Herpes Simplex	Herpes
	Hepatitis B	Hepatitis
	HIV	HIV/AIDS
Bacteria	Chlamydia trachomatis	Chlamydia
	Neisseria Gonorrheae	Gonorrhea
	Neisseria Gonorrheae Treponema pallidum	Gonorrhea Syphilis
Fungi	Treponema pallidum	Syphilis
Fungi Protozoa	Treponema pallidum Hemophilus ducreyi	Syphilis Chancroid

Prevalence & incidence of CT, GC and TV in the African region



<u>Source:</u> World Health Organization, Dept. of Reproductive Health and Research. *Global incidence and prevalence of selected curable sexually transmitted infections – 2008* World Health Organization: Geneva, Switzerland http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/

STI prevalence in pregnant African women



Chlamydia (CT) 3-9%

Gonorrhea (GC) 2-7%

Trichomoniasis (TV) 15-32%

Asymptomatic 10-45%

Fanck (2000); Rastagi (2003); Gray (2001); Farler (2003); Mullick (2005)





Infection with GC, CT, TV


- •3-fold ↑ HIV acquisition risk
- •5-fold 个 pelvic inflammatory disease risk
- •1.5-fold 个 preterm labor risk

Kissinger & Adamski (2013); Laga et al (2007); McClelland et al (2007); Van Der Pol et al (2008); Mavedzenge et al (2010); Moodley et al (2002); Paisarntantiwong et al (1995); Cotch et al (1997); Mullick et al (2005); Minkoff et al (1984); Johnson et al (2011); Azargoon et al (2007); Mathai et al (1998)






Syndromic Management










Patient-reported symptoms Patient complains of vaginal discharge, vulval itching or burning Take history and examine Assess risk ■ Educate and counsel ■ Promote condom use and Abnormal provide condoms NO → discharge or Any other genital disease? NO- Offer HIV counselling and vulval erythema? testing if both facilities are available YES ₩ Use appropriate flowchart for additional treatment Lower abdominal Use flowchart for lower abdominal pain tenderness? TREAT FOR High GC/CT prevalence GONOCOCCAL INFECTION, setting¹ or risk YES > CHLAMYDIA TRACHOMATIS, assessment positive? **BACTERIAL VAGINOSIS AND** TRICHOMONAS VAGINALIS TREAT FOR Vulval oedema/curd TREAT FOR **BACTERIAL VAGINOSIS AND** -like discharge, erythema, CANDIDA ALBICANS TRICHOMONAS VAGINALIS excoriations present? ■ Educate and counsel ■ Promote condom use and provide condoms


■ Offer HIV counselling and testing if both facilities


are available

Patient-reported symptoms

Clinical examination and risk assessment







Advantages

- Simple problem-oriented approach
- Avoids costly diagnostics
- Treats co-morbid infections
- Treatment given at first visit
- Easily integrated into routine healthcare

Bosu WK, Trop Med Int Health 1999;4:114-119; Pettifor et al., Sex Transm Dis 2000;27:371-385





Aim

 To evaluate the diagnostic validity of syndromic algorithms for CT, GC and TV in a pregnant cohort in Kenya





Methods

- Design: Enrollment date from prospective study
- Setting: 2 facilities in Western Kenya
- STI symptoms and signs assessed by study nurses
- Laboratory methods:
 - Wet mount microscopy for TV
 - NAAT for CT/GC

Statistical analysis

- Excluded participants without baseline STI status documented
- Self-reported symptoms and clinical signs per national guidelines
- Laboratory diagnosis for CT/GC/TV as gold standard
- Assessed:
 - Sensitivity
 - Specificity
 - Positive predictive value (PPV)
 - Negative predictive value (NPV)





Validation of Flowcharts

Gold Standard Reference Test (Laboratory assay)

Pos Neg

Pos A E

Syndromic flowchart Neg C

Sensitivity = A/(A+C) Positive predictive value (PPV)= A/(A/B)

Specificity = D/(B+D) **Positive predictive value (NPV)** = C/(C/D)






Results

1,275 (99% of total study population)

Excl. HIV seroconverters (n=25); incomplete STI assessment (n=4)







Results

1,275 (99% of total study population)

Excl. HIV seroconverters (n=25); incomplete STI assessment (n=4)

Median


- Age 22 years (IQR 19-27)
- Gestational age 22 weeks (16-26)

Frequency

- 78% married
- 55% reported condomless sex
- 94% reported no prior STIs
















163 (13%)

No STI


1,112 (87%)

Asymptomatic

Any STI	75%
СТ	74%
GC	91%
TV	66%








*p<0.05; ¹ Clinically assessed signs include abnormal vaginal discharge and cervical mucopus







¹ Clinically assessed signs include abnormal vaginal discharge and cervical mucopus





Approach	Sensitivity	Specificity	PPV	NPV
Self-reported symptoms only ¹	25%	84%	19%	88%

¹ Self-reported symptoms include abnormal vaginal discharge and vaginal itching





Approach	Sensitivity	Specificity	PPV	NPV
Self-reported symptoms only ¹	25%	84%	19%	88%
Clinical signs only ²	19%	89%	21%	88%

² Clinically assessed signs include abnormal vaginal discharge and cervical mucopus





¹ Self-reported symptoms include abnormal vaginal discharge and vaginal itching

Approach	Sensitivity	Specificity	PPV	NPV
Self-reported symptoms only ¹	25%	84%	19%	88%
Clinical signs only ²	19%	89%	21%	88%
Clinical signs & self- reported symptoms ^{1,2}	61%	52%	22%	86%

² Clinically assessed signs include abnormal vaginal discharge and cervical mucopus





¹ Self-reported symptoms include abnormal vaginal discharge and vaginal itching

STI	Sensitivity	Specificity
СТ	61%	51%
GC	67%	50%
TV	67%	52%






All women with laboratory confirmed STIs

$$(n=163)$$

All symptomatic women with laboratory confirmed STIs

$$(n=41)$$



- No self-reported symptoms
- Self-reported symptoms

- No clinical signs
- Clinical signs





Main findings & Implications

- Appreciable STI prevalence, frequently asymptomatic
- Low sensitivity with syndromic diagnosis
- Missed opportunities for clinical intervention
- Improved, accessible STIs diagnostics are needed






Limitations

- Only CT, GC, and TV included
- Wet mount low sensitivity
 - TV prevalence likely underestimated

Garber et al (2005)







Conclusions

- Prevalence of STIs in pregnancy was common
- Improved detection of asymptomatic infections is needed
- Effective STI management could improve maternal health outcomes





Acknowledgements

Mama Salama Study participants and study staff, the Kenyan Ministry of Health, CDC/KEMRI, and Ahero & Bondo District Hospitals

Funding provided by NIH P01 HSD 064915 and CFAR P30 Al27757

Travel funding provided by Edith Anderson Leadership Education Grant











Kenyatta National Hospital/ University of Nairobi John Kinuthia Daniel Matemo James Kiarie

CDC/KEMRI Clement Zeh Lisa Mills University of Washington
Grace John-Stewart
Alison Drake
Katherine Odem-Davis
Barbara Lohman Payne
Barbra Richardson
Jennifer Slyker
Jennifer Unger
Julie Overbaugh
Scott McClelland
Carey Farquhar
Anjuli Wagner
Gwen Ambler



